ArticleJournal of hepatocellular carcinoma2026
A Retrospective Study of Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombus (VP4).
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HAIC-Based Combination Therapy for Advanced Hepatocellular Carcinoma with Vp4 Portal Vein Tumor Thrombus and Child-Pugh B Liver Function: A Case Report.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with hepatocellular carcinoma (HCC) involving main portal vein tumor thrombosis (Vp4) face a dismal prognosis with limited treatment options. While combination therapy comprising hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), and PD-1 inhibitors has emerged as a potential strategy, real-world clinical data regarding its efficacy and safety in this subset of patients remain scarce. Methods: This retrospective study enrolled 35 Vp4 HCC patients who received HAIC combine with TKI and PD-1 inhibitor. Treatment response was evaluated according to mRECIST and RECIST1.1. Survival outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method, and independent prognostic factors were identified via Cox regression analyses. Results: Of 35 patients (mean age 52.7 ± 8.3 years, 97.1% male, 97.1% HBV-infected), 37.1% had extrahepatic metastasis and 57.1% had ≥4 tumors. After a median follow-up of 313 days (IQR, 177.5-464.5), the objective response rate (ORR) by mRECIST was 60.0%. Median OS and PFS were 313 days (95% CI: 257.5-368.5) and 204 days (95% CI: 153.9-254.1) respectively. Hepatic vein tumor thrombus/inferior vena cava tumor thrombus (HVTT/IVCTT) independently predicted worse PFS (HR = 2.860, p = 0.023) and OS (HR = 3.482, p = 0.007), and tumor number ≥4 predicted inferior OS (HR = 2.454, p = 0.020). Grade 3-4 AEs occurred in 45.7% of patients, most commonly elevated AST (34.3%), with no grade 5 events. Conclusion: The combination of HAIC, TKI, and PD-1 inhibitor demonstrates encouraging antitumor activity and a manageable safety profile in patients with Vp4 HCC, indicating its potential as an effective treatment option for this clinically challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.